Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM.

Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527. [Epub ahead of print]

PMID:
30141729
2.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
3.

Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.

Cascione M, Tenenbaum N, Wendt J, Meng X, Schofield L, Cree BAC; PREFERMS investigators.

Mult Scler Relat Disord. 2018 Jul 11;25:50-56. doi: 10.1016/j.msard.2018.07.014. [Epub ahead of print]

4.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

PMID:
29908077
5.

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.

Cree BAC, Arnold DL, Cascione M, Fox EJ, Williams IM, Meng X, Schofield L, Tenenbaum N.

Ther Adv Neurol Disord. 2018 May 20;11:1756286418774338. doi: 10.1177/1756286418774338. eCollection 2018.

6.

Multiple Sclerosis Therapy: Are We Ready for a One-Size-Fits-All Approach?

Cree BAC.

J Neuroophthalmol. 2018 Jun;38(2):258-262. doi: 10.1097/WNO.0000000000000640. No abstract available.

PMID:
29750736
7.

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):789-800. doi: 10.1212/WNL.0000000000005345.

PMID:
29686117
8.

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T.

Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347.

PMID:
29686116
9.

Progressive multifocal leukoencephalopathy after fingolimod treatment.

Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M.

Neurology. 2018 May 15;90(20):e1815-e1821. doi: 10.1212/WNL.0000000000005529. Epub 2018 Apr 18.

10.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
11.

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453. doi: 10.1212/NXI.0000000000000453. eCollection 2018 May.

12.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

13.

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.

Cree BA.

Mult Scler. 2018 Aug;24(9):1161-1162. doi: 10.1177/1352458518760717. Epub 2018 Feb 22. No abstract available.

PMID:
29468947
14.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407. [Epub ahead of print]

PMID:
29310490
15.

The Gut Microbiome in Neuromyelitis Optica.

Zamvil SS, Spencer CM, Baranzini SE, Cree BAC.

Neurotherapeutics. 2018 Jan;15(1):92-101. doi: 10.1007/s13311-017-0594-z. Review.

16.

Ovarian aging is associated with gray matter volume and disability in women with MS.

Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A; University of California, San Francisco MS-EPIC Team,, Bacchetti P, Hauser SL, Oksenberg JR.

Neurology. 2018 Jan 16;90(3):e254-e260. doi: 10.1212/WNL.0000000000004843. Epub 2017 Dec 22.

PMID:
29273686
17.

Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury.

Cree BAC, Niu J, Hoi KK, Zhao C, Caganap SD, Henry RG, Dao DQ, Zollinger DR, Mei F, Shen YA, Franklin RJM, Ullian EM, Xiao L, Chan JR, Fancy SPJ.

Brain. 2018 Jan 1;141(1):85-98. doi: 10.1093/brain/awx312.

PMID:
29244098
18.

Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Eggers EL, Michel BA, Wu H, Wang SZ, Bevan CJ, Abounasr A, Pierson NS, Bischof A, Kazer M, Leitner E, Greenfield AL, Demuth S, Wilson MR, Henry RG, Cree BA, Hauser SL, von Büdingen HC.

JCI Insight. 2017 Nov 16;2(22). pii: 92724. doi: 10.1172/jci.insight.92724. [Epub ahead of print]

19.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.

20.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, Nobuta H, Zhu A, Friessen M, Gerona R, von Büdingen HC, Henry RG, Hauser SL, Chan JR.

Lancet. 2017 Dec 2;390(10111):2481-2489. doi: 10.1016/S0140-6736(17)32346-2. Epub 2017 Oct 10.

21.

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC.

Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15.

22.

Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models.

Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, Crabtree-Hartman E, Sand IK, Gacias M, Zhu Y, Casaccia P, Cree BAC, Knight R, Mazmanian SK, Baranzini SE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10713-10718. doi: 10.1073/pnas.1711235114. Epub 2017 Sep 11. Erratum in: Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8943.

23.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657. [Epub ahead of print]

PMID:
28847219
24.

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Gelfand JM, Cree BAC, Hauser SL.

Neurotherapeutics. 2017 Oct;14(4):835-841. doi: 10.1007/s13311-017-0557-4. Review.

PMID:
28695471
25.

Acute liver injury in a Glatopa-treated patient with MS.

Sabatino JJ Jr, Mehta NJ, Kakar S, Zamvil SS, Cree BAC.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e368. doi: 10.1212/NXI.0000000000000368. eCollection 2017 Jul. No abstract available.

26.

Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis.

Seraji-Bozorgzad N, Khan O, Cree BAC, Bao F, Caon C, Zak I, Razmjou S, Tselis A, Millis S, Bernitsas E.

J Neuroimaging. 2017 Sep;27(5):476-480. doi: 10.1111/jon.12435. Epub 2017 Mar 29.

PMID:
28371088
27.

Onset of secondary progressive MS after long-term rituximab therapy - a case report.

von Büdingen HC, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BA, Henry RG, Hauser SL.

Ann Clin Transl Neurol. 2016 Dec 20;4(1):46-52. doi: 10.1002/acn3.377. eCollection 2017 Jan.

28.

Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Block VJ, Lizée A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM.

J Neurol. 2017 Feb;264(2):316-326. doi: 10.1007/s00415-016-8334-6. Epub 2016 Nov 28.

29.

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.

Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e272. eCollection 2016 Oct.

30.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

31.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

32.

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens.

Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS.

Ann Neurol. 2016 Sep;80(3):443-7. doi: 10.1002/ana.24718. Epub 2016 Aug 4.

33.

Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.

Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R, Caillier SJ, Santaniello A, Lizée A, Himmelstein DS, Baranzini SE, Hollenbach J, Cree BA, Hauser SL, Oksenberg JR, Henry RG.

JAMA Neurol. 2016 Jul 1;73(7):795-802. doi: 10.1001/jamaneurol.2016.0980.

34.

Characterizing retinal structure injury in African-Americans with multiple sclerosis.

Seraji-Bozorgzad N, Reed S, Bao F, Santiago C, Tselis A, Bernitsas E, Caon C, Frohman E, Bhatti MT, Cree BA, Khan O.

Mult Scler Relat Disord. 2016 May;7:16-20. doi: 10.1016/j.msard.2016.02.009. Epub 2016 Feb 12.

PMID:
27237751
35.

Statistical Considerations for an Adaptive Design for a Serious Rare Disease.

Patra K, Cree BAC, Katz E, Pulkstenis E, Dmitrienko A, Cutter G.

Ther Innov Regul Sci. 2016 May;50(3):375-384. doi: 10.1177/2168479015619203.

PMID:
30227072
36.

Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.

Block VA, Pitsch E, Tahir P, Cree BA, Allen DD, Gelfand JM.

PLoS One. 2016 Apr 28;11(4):e0154335. doi: 10.1371/journal.pone.0154335. eCollection 2016. Review.

37.

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil SS.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777-82. doi: 10.1073/pnas.1603907113. Epub 2016 Apr 13.

38.

Steering through complexity: management approaches in multiple sclerosis.

Cree BA, Hartung HP.

Curr Opin Neurol. 2016 Jun;29(3):263-71. doi: 10.1097/WCO.0000000000000332. Review.

PMID:
27058222
39.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.

Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum in: Lancet. 2017 Jan 21;389(10066):254.

PMID:
26827074
40.

Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.

Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E.

Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14.

41.

Fulminant Demyelinating Diseases of the Central Nervous System.

Bevan CJ, Cree BA.

Semin Neurol. 2015 Dec;35(6):656-66. doi: 10.1055/s-0035-1564682. Epub 2015 Nov 23. Review.

PMID:
26595866
42.

Placebo controlled trials in neuromyelitis optica are needed and ethical.

Cree BA.

Mult Scler Relat Disord. 2015 Nov;4(6):536-45. doi: 10.1016/j.msard.2015.07.017. Epub 2015 Jul 31. Review.

43.

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D.

Mult Scler. 2016 Sep;22(10):1297-305. doi: 10.1177/1352458515616701. Epub 2015 Nov 19.

44.

Diagnosing Encephalitis, Not Otherwise Specified-Reply.

Gelfand JM, Tihan T, Cree BA.

JAMA Neurol. 2015 Jun;72(6):726-7. doi: 10.1001/jamaneurol.2015.0548. No abstract available.

PMID:
26053447
45.

Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.

Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin DS, Cree BA, Hauser SL, Henry RG.

JAMA Neurol. 2015 Aug;72(8):897-904. doi: 10.1001/jamaneurol.2015.0993.

46.

Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis.

Orengo JP, Pekmezci M, Cree BA.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e101. doi: 10.1212/NXI.0000000000000101. eCollection 2015 Jun. No abstract available.

47.

Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium.

Neurology. 2015 Apr 28;84(17):1805-15. doi: 10.1212/WNL.0000000000001520. Epub 2015 Apr 3. Review.

48.

An ImmunoChip study of multiple sclerosis risk in African Americans.

Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, Moré JM, Gourraud PA, McCauley JL, Beecham AH; International Multiple Sclerosis Genetics Consortium, Piccio L, Herbert J, Khan O, Cohen J, Stone L, Santaniello A, Cree BA, Onengut-Gumuscu S, Rich SS, Hauser SL, Sawcer S, Oksenberg JR.

Brain. 2015 Jun;138(Pt 6):1518-30. doi: 10.1093/brain/awv078. Epub 2015 Mar 28.

49.

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076. eCollection 2015 Jun.

50.

Demyelinating disease: Is TOPIC the last trial for clinically isolated syndrome?

Cree BA.

Nat Rev Neurol. 2015 Jan;11(1):6-7. doi: 10.1038/nrneurol.2014.239. Epub 2014 Dec 16. No abstract available.

PMID:
25511890

Supplemental Content

Support Center